JP2022511471A5 - - Google Patents

Info

Publication number
JP2022511471A5
JP2022511471A5 JP2021531486A JP2021531486A JP2022511471A5 JP 2022511471 A5 JP2022511471 A5 JP 2022511471A5 JP 2021531486 A JP2021531486 A JP 2021531486A JP 2021531486 A JP2021531486 A JP 2021531486A JP 2022511471 A5 JP2022511471 A5 JP 2022511471A5
Authority
JP
Japan
Prior art keywords
combination according
mammal
administered
inhibitor
ddri
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021531486A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022511471A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/001292 external-priority patent/WO2020115548A1/en
Publication of JP2022511471A publication Critical patent/JP2022511471A/ja
Publication of JP2022511471A5 publication Critical patent/JP2022511471A5/ja
Priority to JP2024193520A priority Critical patent/JP2025013486A/ja
Pending legal-status Critical Current

Links

JP2021531486A 2018-12-03 2019-12-03 放射性免疫複合体とｄｎａの損傷および修復阻害剤の併用療法 Pending JP2022511471A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024193520A JP2025013486A (ja) 2018-12-03 2024-11-05 放射性免疫複合体とｄｎａの損傷および修復阻害剤の併用療法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862774847P 2018-12-03 2018-12-03
US62/774,847 2018-12-03
PCT/IB2019/001292 WO2020115548A1 (en) 2018-12-03 2019-12-03 Radioimmunoconjugates and dna damage and repair inhibitor combination therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024193520A Division JP2025013486A (ja) 2018-12-03 2024-11-05 放射性免疫複合体とｄｎａの損傷および修復阻害剤の併用療法

Publications (2)

Publication Number Publication Date
JP2022511471A JP2022511471A (ja) 2022-01-31
JP2022511471A5 true JP2022511471A5 (https=) 2022-12-12

Family

ID=70973593

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021531486A Pending JP2022511471A (ja) 2018-12-03 2019-12-03 放射性免疫複合体とｄｎａの損傷および修復阻害剤の併用療法
JP2021531492A Pending JP2022513700A (ja) 2018-12-03 2019-12-03 放射性免疫複合体とチェックポイント阻害剤の併用療法
JP2024193520A Pending JP2025013486A (ja) 2018-12-03 2024-11-05 放射性免疫複合体とｄｎａの損傷および修復阻害剤の併用療法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021531492A Pending JP2022513700A (ja) 2018-12-03 2019-12-03 放射性免疫複合体とチェックポイント阻害剤の併用療法
JP2024193520A Pending JP2025013486A (ja) 2018-12-03 2024-11-05 放射性免疫複合体とｄｎａの損傷および修復阻害剤の併用療法

Country Status (18)

Country Link
US (5) US20220088231A1 (https=)
EP (2) EP3890790A4 (https=)
JP (3) JP2022511471A (https=)
KR (2) KR20210099073A (https=)
CN (4) CN117482261A (https=)
AU (2) AU2019394888A1 (https=)
BR (2) BR112021010799A2 (https=)
CA (2) CA3119915A1 (https=)
CL (2) CL2021001432A1 (https=)
EA (2) EA202191557A1 (https=)
IL (2) IL283598A (https=)
MA (2) MA54399A (https=)
MX (2) MX2021006408A (https=)
PE (2) PE20211286A1 (https=)
PH (2) PH12021551282A1 (https=)
SG (2) SG11202105112RA (https=)
WO (2) WO2020115556A1 (https=)
ZA (1) ZA202103429B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020142583A1 (en) * 2019-01-04 2020-07-09 Actinium Pharmaceuticals, Inc. Methods for treating cancer using combinations of parp inhibitors and antibody radioconjugates
BR112021022237A2 (pt) 2019-05-10 2022-03-29 Janssen Biotech Inc Queladores macrocíclicos e métodos de uso dos mesmos
AU2021206233A1 (en) * 2020-01-10 2022-08-11 Fusion Pharmaceuticals Inc. Sustained immunotherapy
WO2021207086A1 (en) * 2020-04-06 2021-10-14 Fusion Pharmaceuticals Inc. Tem-1-targeted radioimmunoconjugates and uses thereof
US20220267450A1 (en) 2020-10-14 2022-08-25 Viridian Therapeutics, Inc. Compositions and methods for treatment of thyroid eye disease
US20250275946A1 (en) * 2021-02-02 2025-09-04 Unm Rainforest Innovations Combination therapy for the treatment of cancer
US11541134B1 (en) 2021-08-02 2023-01-03 Rayzebio, Inc. Stabilized compositions of radionuclides and uses thereof
EP4384219A4 (en) 2021-08-10 2025-06-18 Viridian Therapeutics, Inc. COMPOSITIONS, DOSAGES AND METHODS FOR THE TREATMENT OF THYROID EYE DISEASE
US20250339571A1 (en) * 2021-08-27 2025-11-06 Actinium Pharmaceuticals, Inc. Radioimmunoconjugates targeting phosphatidylserine for use in the treatment of cancer
AU2021466827A1 (en) * 2021-09-29 2024-04-11 Fusion Pharmaceuticals Inc. Egfrviii-targeted compounds and uses thereof
TW202325344A (zh) * 2021-11-02 2023-07-01 加拿大商融合製藥公司 治療癌症之方法
US20250177581A1 (en) * 2022-01-28 2025-06-05 Fusion Pharmaceuticals Inc. Ntsr1-targeted radiopharmaceuticals and dna damage response inhibitor combination therapy

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5053503A (en) * 1989-02-17 1991-10-01 Centocor Chelating agents
WO1992022324A1 (en) 1991-06-14 1992-12-23 Xoma Corporation Microbially-produced antibody fragments and their conjugates
BRPI9809391B8 (pt) 1997-04-14 2021-05-25 Amgen Res Munich Gmbh processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica
US7736651B1 (en) * 2000-11-24 2010-06-15 Sloan-Kettering Institute For Cancer Research Alpha emitting constructs and uses thereof
EP1838736B1 (en) * 2005-01-05 2013-03-06 Biogen Idec MA Inc. Cripto binding molecules
AU2007245164A1 (en) * 2006-03-28 2007-11-08 Biogen Idec Ma Inc. Anti-IGF-IR antibodies and uses thereof
WO2011060233A1 (en) * 2009-11-11 2011-05-19 The Trustees Of The University Of Pennsylvania Anti-tem1 antibodies and uses thereof
ES2978177T3 (es) 2009-12-02 2024-09-06 Immunomedics Inc Combinación de radio inmunoterapia y conjugados anticuerpo-fármaco para mejorar la terapia contra el cáncer
GB201120779D0 (en) 2011-12-02 2012-01-11 Immodulon Therapeutics Ltd Cancer therapy
GB201403875D0 (en) * 2014-03-05 2014-04-16 Cantargia Ab Novel antibodies and uses thereof
PT3134127T (pt) * 2014-04-25 2020-04-09 Rinat Neuroscience Corp Conjugados de anticorpo-fármaco com alta carga de fármaco
US10092645B2 (en) 2014-06-17 2018-10-09 Medimmune Limited Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy
EP3280439A1 (en) * 2015-04-07 2018-02-14 INSERM - Institut National de la Santé et de la Recherche Médicale Anti-pd-l1 immunotoxin for use in therapy
US11149087B2 (en) * 2015-04-20 2021-10-19 Etubics Corporation Methods and compositions for combination immunotherapy
EP3285809B1 (en) * 2015-04-20 2019-09-11 eFFECTOR Therapeutics, Inc. Inhibitors of immune checkpoint modulators for use in treating cancer and infections
AU2016271138A1 (en) * 2015-05-29 2017-12-07 Merrimack Pharmaceuticals, Inc. Combination cancer therapies
MX2018008345A (es) * 2016-01-11 2018-12-06 Univ Leland Stanford Junior Proteínas quiméricas y métodos de inmunoterapia.
EP3202788A1 (en) 2016-02-05 2017-08-09 MediaPharma S.r.l. Endosialin-binding antibody
TWI910495B (zh) * 2016-05-13 2026-01-01 美商再生元醫藥公司 藉由投予pd-1抑制劑治療皮膚癌之方法
US11633506B2 (en) * 2016-07-18 2023-04-25 Wisconsin Alumni Research Foundation Using targeted radiotherapy (TRT) to drive anti-tumor immune response to immunotherapies
EP3496707A4 (en) 2016-08-09 2020-03-25 Angimmune, LLC Treatment of cancer using a combination of immunomodulation and check point inhibitors
WO2018038680A1 (en) * 2016-08-24 2018-03-01 Scinopharm Taiwan, Ltd. Processes for preparing olaparib
WO2018049474A1 (en) * 2016-09-16 2018-03-22 Bionomics Limited Antibody and checkpoint inhibitor combination therapy
US11273155B2 (en) * 2016-12-12 2022-03-15 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and immune checkpoint inhibitor
WO2018153975A1 (en) * 2017-02-24 2018-08-30 Bayer As Combination therapy comprising a radiopharmaceutical and a dna-repair inhibitor
MA48861A (fr) * 2017-05-05 2020-04-01 Fusion Pharmaceuticals Inc Améliorations pharmacocinétiques de chélates bifonctionnels et leurs utilisations
US10093741B1 (en) * 2017-05-05 2018-10-09 Fusion Pharmaceuticals Inc. IGF-1R monoclonal antibodies and uses thereof
WO2018204872A2 (en) * 2017-05-05 2018-11-08 Fusion Pharmaceuticals Inc. Igf-1r monoclonal antibodies and uses thereof
AU2018331430A1 (en) * 2017-09-13 2020-03-19 Radimmune Therapeutics, Inc. Melanin antibodies and uses thereof
EP3713607A1 (en) * 2017-11-22 2020-09-30 Nordic Nanovector ASA Radioimmunoconjugates in combination with other drugs as treatment against nhl
US20220125960A1 (en) * 2019-02-21 2022-04-28 Bayer Aktiengesellschaft Combination of pd-1/pd-l1 inhibitors and targeted thorium conjugates

Similar Documents

Publication Publication Date Title
JP2022511471A5 (https=)
Poty et al. α-emitters for radiotherapy: from basic radiochemistry to clinical studies—part 2
Seidl Radioimmunotherapy with α-particle-emitting radionuclides
Milenic et al. Targeting of HER2 antigen for the treatment of disseminated peritoneal disease
DK2914302T3 (en) RADIOACTIVALLY MARKED ANTIBODY AND USES OF IT
JP2022516170A5 (https=)
Milenic et al. Potentiation of high-LET radiation by gemcitabine: targeting HER2 with trastuzumab to treat disseminated peritoneal disease
Navarro-Teulon et al. General overview of radioimmunotherapy of solid tumors
JP2022090047A (ja) 血液悪性疾患を処置するための低用量抗体に基づく方法
JP2020523029A5 (https=)
JP2022513700A5 (https=)
Lin et al. The evolution of antibodies into versatile tumor-targeting agents
US20260053963A1 (en) Radioconjugates targeting cd33 in the treatment of breast cancer
CA3196402A1 (en) Combination radioimmunotherapy and cd47 blockade in the treatment of cancer
Mohajershojai et al. In vitro characterization of 177Lu-DOTA-M5A anti-carcinoembryonic antigen humanized antibody and HSP90 inhibition for potentiated radioimmunotherapy of colorectal cancer
US20240216554A1 (en) Radioimmunoconjugates directed to nkg2d ligands for the treatment of cancer
US9289519B2 (en) Alpha emitting constructs and uses thereof
Rousseau et al. Radiolabeled Antibodies for Cancer Radioimmunotherapy
CN101405399A (zh) 抑制乳腺癌干细胞的生长和转移
US12539340B2 (en) Radioconjugates targeting CD33 in the treatment of cancers
JP5064608B2 (ja) アルファ粒子放出構成物およびその使用方法
Gencsoy Eker et al. A comprehensive review of the mechanisms and clinical development of monoclonal antibodies in cancer therapy
EP3706785B1 (en) Combination of radionuclide-conjugated antibodies for treatment of a hematological malignancies
Mahalingam et al. A trial of radiolabeled antibody yttrium‐90–FF‐21101 for the treatment of advanced ovarian and other cancers
Cianfriglia Ceacam1 is a privileged cell surface antigen to design novel scfv mediated-immunotherapies of melanoma, lung cancer and other types of tumors